206 related articles for article (PubMed ID: 10718179)
1. Urinary tissue factor levels in patients with bladder and prostate cancer.
Lwaleed BA; Francis JL; Chisholm M
Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
[TBL] [Abstract][Full Text] [Related]
2. Urinary tissue factor levels in patients with breast and colorectal cancer.
Lwaleed BA; Chisholm M; Francis JL
J Pathol; 1999 Feb; 187(3):291-4. PubMed ID: 10398081
[TBL] [Abstract][Full Text] [Related]
3. Monocyte tissue factor levels in cancer patients.
Lwaleed BA; Francis JL; Chisholm M
Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor assays as diagnostic tools for cancer? Correlation between urinary and monocyte tissue factor activity.
Lwaleed BA; Francis JL; Chisholm M
J Hematother Stem Cell Res; 1999 Dec; 8(6):659-68. PubMed ID: 10645774
[TBL] [Abstract][Full Text] [Related]
5. Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread?
Adamson AS; Francis JL; Witherow RO; Snell ME
Br J Urol; 1993 May; 71(5):587-92. PubMed ID: 7686076
[TBL] [Abstract][Full Text] [Related]
6. Urinary tissue factor: a potential marker of disease.
Lwaleed BA; Bass PS; Francis JL
J Pathol; 1999 May; 188(1):3-8. PubMed ID: 10398132
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
10. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
[TBL] [Abstract][Full Text] [Related]
11. Urinary tissue factor levels in neoplastic diseases.
Lwaleed BA; Francis JL; Chisholm M
Ann Saudi Med; 2000; 20(3-4):197-201. PubMed ID: 17322656
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
13. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
15. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies.
Perabo F; Sharma S; Gierer R; Wirger A; Fimmers R; Steiner G; Adam M; Schultze-Seemann W
Indian J Cancer; 2001 Mar; 38(1):1-7. PubMed ID: 14758878
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of zinc levels in benign and malignant lesions of the prostate.
Goel T; Sankhwar SN
Scand J Urol Nephrol; 2006; 40(2):108-12. PubMed ID: 16608807
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
20. Urine based markers of urological malignancy.
Konety BR; Getzenberg RH
J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
